Publications by authors named "Bernard Roubert"

Claim this Profile
A
A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China.
Jie Jin, Zhihua Ran, Emanuele Noseda, Bernard Roubert, Matthieu Marty

Front Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
Piotr Ponikowski, Robert J Mentz, Adrian F Hernandez, Javed Butler, Muhammad Shahzeb Khan, Bernard Roubert

Eur Heart J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency.
Muhammad Shahzeb Khan, Stefan D Anker, Tim Friede, Ewa A Jankowska, Marco Metra, Bernard Roubert

J Card Fail· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
Javed Butler, Muhammad Shahzeb Khan, Claudio Mori, Gerasimos S Filippatos, Piotr Ponikowski, Bernard Roubert

Eur J Heart Fail· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia.
Yanhua Ding, Xiaoxue Zhu, Xiaojiao Li, Hong Zhang, Min Wu, Bernard Roubert

Clin Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
Frank Richard, Jan Jaap van Lier, Bernard Roubert, Teba Haboubi, Udo-Michael Göhring

Am J Hematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
Stefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, Gerasimos Filippatos, Josep Comin-Colet, Bernard Roubert

Eur J Heart Fail· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Claudia Trenkwalder, Juliane Winkelmann, Wolfgang Oertel, Garth Virgin, Bernard Roubert

Mov Disord· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
Dirk J van Veldhuisen, Piotr Ponikowski, Peter van der Meer, Marco Metra, Michael Böhm, Bernard Roubert

Circulation· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
Christian Breymann, Nils Milman, Anna Mezzacasa, Roubert Bernard, Joachim Dudenhausen

J Perinat Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Piotr Ponikowski, Dirk J van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Bernard Roubert

Eur Heart J· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.
Michael Hedenus, Torbjörn Karlsson, Heinz Ludwig, Beate Rzychon, Marcel Felder, Bernard Roubert

Med Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Iain C Macdougall, Andreas H Bock, Fernando Carrera, Kai-Uwe Eckardt, Carlo Gaillard, Bernard Roubert

Nephrol Dial Transplant· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
Piotr Ponikowski, Dirk J van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Bernard Roubert

ESC Heart Fail· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Iain C Macdougall, Andreas Bock, Fernando Carrera, Kai-Uwe Eckardt, Carlo Gaillard, Bernard Roubert

Nephrol Dial Transplant· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Michael Stadler, Bernard Roubert

Haematologica· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Dudley J Pennell, John B Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Bernard Roubert

Haematologica· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
John B Porter, Kai-Hsin Lin, Photis Beris, Gian Luca Forni, Ali Taher, Bernard Roubert

Eur J Haematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.
Ali Taher, Mohsen S Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Bernard Roubert

Eur J Haematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.
Ali Taher, Mohsen S Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Bernard Roubert

Eur J Haematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.
Vip Viprakasit, Hishamshah Ibrahim, Shau-Yin Ha, Phoebe Joy Ho, Chi-Kong Li, Bernard Roubert

Int J Hematol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Dudley J Pennell, John B Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Bernard Roubert

Haematologica· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.
Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Bernard Roubert

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Arnold Ganser, Bernard Roubert

Leuk Res· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Dudley J Pennell, John B Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Bernard Roubert

Blood· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis